Published • loading... • Updated
Novartis Abandons Heart Drug After Surprising Failure in Key Study
Summary by BizToc
4 Articles
4 Articles
The results of phase III with pelacarsen represent a jar of cold water to the hypothesis that this compound would protect against the development of heart diseases Read
·Madrid, Spain
Read Full Article
Naiarabrocal Cardiology Congress of the Mazazo AHA to research drugs aimed at reducing lipoprotein (a), or Lp(a). Pelacarsen, one of the most advanced compounds in this field, has failed in a phase III clinical trial by failing to reach its primary objective of reducing the risk of major cardiovascular events, which included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization.Lp(a) is a p…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
